JMP cited strong prescription growth of 7% quarter-over-quarter for Exelixis’s cancer drug cabozantinib as the primary driver for the anticipated earnings beat. This follows what the firm described as ...

JMP cited strong prescription growth of 7% quarter-over-quarter for Exelixis’s cancer drug cabozantinib as the primary driver for the anticipated earnings beat.